Bayer Other Non-Current Liabilities 2012-2025 | BAYRY
Bayer other non-current liabilities from 2012 to 2025. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Bayer other non-current liabilities for the quarter ending December 31, 2025 were $15.037B, a 3.01% increase year-over-year.
- Bayer other non-current liabilities for 2025 were $15.037B, a 3.01% increase from 2024.
- Bayer other non-current liabilities for 2024 were $14.598B, a 8.61% decline from 2023.
- Bayer other non-current liabilities for 2023 were $15.973B, a 7.27% decline from 2022.
|
Bayer Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $15,037 |
| 2024 | $14,598 |
| 2023 | $15,973 |
| 2022 | $17,225 |
| 2021 | $23,967 |
| 2020 | $17,240 |
| 2019 | $16,642 |
| 2018 | $17,693 |
| 2017 | $12,430 |
| 2016 | $15,818 |
| 2015 | $15,715 |
| 2014 | $20,391 |
| 2013 | $12,894 |
| 2012 | $15,135 |
| 2011 | $14,349 |
|
Bayer Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2025-12-31 | $15,037 |
| 2025-09-30 | $14,088 |
| 2025-06-30 | $14,171 |
| 2025-03-31 | $13,549 |
| 2024-12-31 | $14,598 |
| 2024-09-30 | $15,054 |
| 2024-06-30 | $15,311 |
| 2024-03-31 | $15,980 |
| 2023-12-31 | $15,973 |
| 2023-09-30 | $16,075 |
| 2023-06-30 | $16,445 |
| 2023-03-31 | $16,486 |
| 2022-12-31 | $17,225 |
| 2022-09-30 | $16,371 |
| 2022-06-30 | $19,209 |
| 2022-03-31 | $21,975 |
| 2021-12-31 | $23,967 |
| 2021-09-30 | $22,210 |
| 2021-06-30 | $22,193 |
| 2021-03-31 | $19,029 |
| 2020-12-31 | $17,240 |
| 2020-09-30 | $18,972 |
| 2020-06-30 | $17,019 |
| 2020-03-31 | $15,959 |
| 2019-12-31 | $16,642 |
| 2019-09-30 | $18,342 |
| 2019-06-30 | $18,835 |
| 2019-03-31 | $17,849 |
| 2018-12-31 | $17,693 |
| 2018-09-30 | $14,273 |
| 2018-06-30 | $14,912 |
| 2018-03-31 | $13,586 |
| 2017-12-31 | $12,430 |
| 2017-09-30 | $20,545 |
| 2017-06-30 | $14,012 |
| 2017-03-31 | $17,584 |
| 2016-12-31 | $15,818 |
| 2016-09-30 | $19,509 |
| 2016-06-30 | $19,097 |
| 2016-03-31 | $18,203 |
| 2015-12-31 | $15,715 |
| 2015-09-30 | $16,579 |
| 2015-06-30 | $15,897 |
| 2015-03-31 | $18,868 |
| 2014-12-31 | $20,391 |
| 2014-09-30 | $18,010 |
| 2014-06-30 | $16,470 |
| 2014-03-31 | $14,741 |
| 2013-12-31 | $12,894 |
| 2013-09-30 | $13,299 |
| 2013-06-30 | $13,614 |
| 2013-03-31 | $15,391 |
| 2012-12-31 | $15,135 |
| 2012-09-30 | $15,094 |
| 2012-06-30 | $14,923 |
| 2012-03-31 | $13,548 |
| 2011-12-31 | $14,349 |
| 2011-09-30 | $13,845 |
| 2011-06-30 | $12,944 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $46.178B | $51.552B |
| Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |